

"Express Mail" Label No. EV 330852005 US


Date of Deposit April 8, 2004

PATENT
Atty. Docket No.: 019633-000129US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By:


Jo Ann Honcik Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.:

Filed: April 8, 2004

For: THE LOS LOCUS FROM C.
JEJUNI

Customer No. 20350

Examiner:

Art Unit:

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on the attached documents (see list of Enclosures at bottom) are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/303,128, filed November 21, 2002 (Attorney Docket No. 019633-000112US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:jhd

Enclosures: IDS of 11/21/02 w/ PTO/SB/08B citing refs. AA-AX (w/ Examiner initialed copy)
Supplemental IDS of 2/27/03 w/ PTO/SB/08B citing ref. AA (w/ Examiner initialed copy)
PTO-892 (Paper No. 0104) citing refs. U and V

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.:

Filed: Herewith

For: NUCLEIC ACIDS ENCODING
BETA-1,4-GALNAC TRANSFERASE

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Beth L. Kelly", written in a cursive style.

Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK/lle
SF 1404050 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	
Filing Date	Herewith
First Named Inventor	Gilbert, Michel, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	019633-000112US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,352,670	10-04-1994	Venot, et al.	
	AB	US-5,374,541	12-20-1994	Wong, et al.	
	AC	US-5,545,553	08-13-1996	Gotschlich	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴ Kind Code ⁴ (if known)				
	AD	WO	92/16640	10-01-1992	The Scripps Research Institute		<input type="checkbox"/>
	AE	WO	96/32491	10-17-1996	Cytel Corp.		<input type="checkbox"/>
	AF	WO	99/49051 A1	09-30-1999	National Research Council of Canada		<input type="checkbox"/>
							<input type="checkbox"/>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AG	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)	
	AH	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 250-255 (1994c)	
	AI	ASPINALL, et al. " Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes O:1, O:4, O:23, and O:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)	
	AJ	ASPINALL, et al. "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)	
	AK	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9988-9997 (1992)	
	AL	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1 " J. Am. Chem. Soc., 116: 1149-1150 (1994)	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1404050 v1

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	Herewith
		First Named Inventor	Gilbert, Michel, et. al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2	of 2	Attorney Docket Number	019633-000112US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	GILBERT et al., "Cloning of the Lipooligosaccharide α -2,3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria Meningitidis</i> and <i>Neisseria Gonorrhoeae</i> ," Journal of Biological Chemistry, Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1996)	
	AN	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in <i>Campylobacter Jejuni</i> OH4384," The Journal of Biological Chemistry, Vol. 275, No. 6, pp. 3896-3906, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11, 2000)	
	AO	ITO et al., "Synthesis of Bioactive Sialosides" Pure Appl. Chem., 65: 753 (1993)	
	AP	KUROKI, "Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain β -N-Acetylglucosamine Residues" Ann. Neurol., 33: 243-247 (1993)	
	AQ	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen <i>Campylobacter Jejuni</i> Reveals Hypervariable Sequences," Nature, Vol. 403, pp. 665-668, (February 10, 2000)	
	AR	PENNER, et al., "Diversity of Lipopolysaccharide Structures in <i>Campylobacter Jejuni</i> ," The Journal of Infectious Diseases, Vol. 176, No. 2, pp. S135-S138, (December 1997)	
	AS	PRENDERGAST, et al., "Lipopolysaccharides from <i>Campylobacter Jejuni</i> O:41 Strains Associated with Guillain-Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," Infection and Immunity, Vol. 66, No. 8, pp. 3649-3677, (August 1998)	
	AT	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," Critical Reviews in Microbiology, Vol. 22, No. 3, pp. 139-180, (1996)	
	AU	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz ¹ H and ¹³ C NMR Spectroscopy" J. Am. Chem. Soc., 108: 2068-2080 (1986)	
	AV	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with <i>Campylobacter Jejuni</i> Bearing Lipopolysaccharide Molecules that Mimic Human Ganglioside GD3," Infection and Immunity, Vol. 64, No. 8, pp. 2945-2949, (August 1996)	
	AW	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in <i>Neisseria meningitidis</i> " J. Biol. Chem., 271: 19166-19173 (1996)	
	AX	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in <i>Campylobacter Jejuni</i> ," Microbiology, Vol. 145, No. 2, pp. 379-388, (February 1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1404050 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>1</u> of <u>2</u>		Complete if Known	
		Application Number	
		Filing Date	Herewith
		First Named Inventor	Gilbert, Michel, et. al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	019633-000112US

JCT 14 U.S. PTO
10X803128
11/21/02

U.S. PATENT DOCUMENTS						
Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AS 245 87	AA	US-5,352,670		10-04-1994	Venot, et al.	
	AB	US-5,374,541		12-20-1994	Wong, et al.	
	AC	US-5,545,553		08-13-1996	Gotschlich	
		US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AD	WO	92/16640		10-01-1992	The Scripps Research Institute		<input type="checkbox"/>
	AE	WO	96/32491		10-17-1996	Cytel Corp.		<input type="checkbox"/>
	AF	WO	99/49051	A1	09-30-1999	National Research Council of Canada		<input type="checkbox"/>
								<input type="checkbox"/>

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AS	AG	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)	
	AH	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 250-255 (1994c)	
	AI	ASPINALL, et al., "Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes O:1, O:4, O:23, and O:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)	
	AJ	ASPINALL, et al., "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)	
	AK	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9989-9997 (1992)	
	AL	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1" J. Am. Chem. Soc., 116: 1149-1150 (1994)	

Examiner Signature	<u>Swope</u>	Date Considered	<u>1/16/04</u>
--------------------	--------------	-----------------	----------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1404050 v1

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	Herewith
		First Named Inventor	Gilbert, Michel, et. al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	019633-000112US
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	AM	GILBERT et al., "Cloning of the Lipooligosaccharide α-2,3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria Meningitidis</i> and <i>Neisseria Gonorrhoeae</i> ," <i>Journal of Biological Chemistry</i> , Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1998)	
	AN	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in <i>Campylobacter Jejuni</i> OH4384," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 6, pp. 3898-3908, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11, 2000)	
	AO	ITO et al., "Synthesis of Bioactive Sialosides" <i>Pure Appl. Chem.</i> , 65: 753 (1993)	
	AP	KUROKI, "Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain β-N-Acetylglucosamine Residues" <i>Ann. Neurol.</i> , 33: 243-247 (1993)	
	AQ	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen <i>Campylobacter Jejuni</i> Reveals Hypervariable Sequences," <i>Nature</i> , Vol. 403, pp. 665-668, (February 10, 2000)	
	AR	PENNER, et al., "Diversity of Lipopolysaccharide Structures in <i>Campylobacter Jejuni</i> ," <i>The Journal of Infectious Diseases</i> , Vol. 176, No. 2, pp. S135-S138, (December 1997)	
	AS	PRENDERGAST, et al., "Lipopolysaccharides from <i>Campylobacter Jejuni</i> O:41 Strains Associated with Guillain-Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," <i>Infection and Immunity</i> , Vol. 66, No. 8, pp. 3649-3677, (August 1998)	
	AT	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," <i>Critical Reviews in Microbiology</i> , Vol. 22, No. 3, pp. 139-180, (1996)	
	AU	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz 1H and C NMR Spectroscopy" <i>J. Am. Chem. Soc.</i> , 108: 2068-2080 (1986)	
	AV	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with <i>Campylobacter Jejuni</i> Bearing Lipopolysaccharide Molecules that Mimic Human Ganglioside GD3," <i>Infection and Immunity</i> , Vol. 64, No. 8, pp. 2945-2949, (August 1996)	
	AW	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in <i>Neisseria meningitidis</i> " <i>J. Biol. Chem.</i> , 271: 19186-19173 (1996)	
	AX	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in <i>Campylobacter Jejuni</i> ," <i>Microbiology</i> , Vol. 145, No. 2, pp. 379-388, (February 1999)	

8/5/16/04
Biological

Examiner Signature	<i>Shupe</i>	Date Considered	1/16/04
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1404050 v1

BEST AVAILABLE COPY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 019633-000112US
Client Reference No.: 10983-1A

Assistant Commissioner for Patents
Washington, D.C. 20231

On 2/27/03

TOWNSEND and TOWNSEND and CREW LLP

By: London Clark

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/303,128

Filed: November 21, 2002

For: NUCLEIC ACIDS ENCODING
BETA-1,4-GALNAC TRANSFERASE

Examiner: Unassigned

Art Unit: 1652

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK/lhc
SF 1436766 v1

(use as many sheets as necessary)

1

Q

1

Attorney Docket Number	019633-000112US
------------------------	-----------------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete If Known

Application Number	10/303,128
Filing Date	November 21, 2002
First Named Inventor	Gilbert, Michel, et. al.
Art Unit	1652
Examiner Name	Unassigned
Attorney Docket Number	019633-000112US

FOREIGN PATENT DOCUMENTS

[illegible]

RECEIVED
MAR 07 2003
TECH CENTER 1600/2900

Examiner Signature	<i>[Signature]</i>	Date Considered	1/16/04
-----------------------	--------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Notice of References Cited	Application/Control No. 10/303,128	Applicant(s)/Patent Under Reexamination GILBERT ET AL.	
	Examiner Sheridan L. Swope	Art Unit 1652	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ausubel et al Protein Expression In: Current Protocols in Molecular Biology Wiley and Sons, Inc. 1987 Chapter 16.
	V	Tomb et al The complete genome sequence of the gastric pathogen Helicobacter pylori. Swiss-Prot Acc#A64547. Alignment with SEQ ID NO: 17.
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.